The importance of choice in the rollout of ARV-based prevention to user groups in Kenya and South Africa: A qualitative study

Journal of the International AIDS Society

Volumn 17, Issue 3, 2014, Pages

  Mack, Natasha ^a   Evens, Emily M ^a   Tolley, Elizabeth E ^a   Brelsford, Kate ^b   MacKenzie, Caroline ^a   Milford, Cecilia ^c   Smit, Jennifer A ^c   Kimani, Joshua ^d  

^a FAMILY HEALTH INTERNATIONAL   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c Overport   (South Africa)

^d Kenya Aids Control Project   (Kenya)

Author keywords

ARV based HIV prevention methods; HIV prevention; Pre exposure prophylaxis; Sub Saharan Africa; Women

Indexed keywords

ALCOHOL; ANTIRETROVIRUS AGENT; ORAL CONTRACEPTIVE AGENT; TENOFOVIR;

ADOLESCENT; ADULT; ARTICLE; CONDOM; DRUG USE; FEMALE; GEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INFORMATION PROCESSING; KENYA; PILL; PROSTITUTION; QUALITATIVE RESEARCH; SECONDARY ANALYSIS; SEXUAL BEHAVIOR; SEXUAL INTERCOURSE; SOUTH AFRICA; THEMATIC ANALYSIS; CHEMOPROPHYLAXIS; HIV INFECTIONS; MALE; PATIENT ATTITUDE; PRE-EXPOSURE PROPHYLAXIS; PROCEDURES; YOUNG ADULT;

ADOLESCENT; ANTI-RETROVIRAL AGENTS; CHEMOPREVENTION; FEMALE; FOCUS GROUPS; HIV INFECTIONS; HUMANS; KENYA; MALE; PATIENT ACCEPTANCE OF HEALTH CARE; PRE-EXPOSURE PROPHYLAXIS; SOUTH AFRICA; YOUNG ADULT;

EID: 84915745190     PISSN: None     EISSN: 17582652     Source Type: Journal    
DOI: 10.7448/IAS.17.3.19157     Document Type: Article

References (23)

1. Person AK, Hicks CB. Pre-exposure prophylaxis-one more tool for HIV prevention. Curr HIV Res. 2012;10(2):117-22.
2. Baeten J, Celum C. Oral antiretroviral chemoprophylaxis: current status. Curr Opin HIV AIDS. 2012;7(6):514-9.
3. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587-99.
4. Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367(5):411-22.
5. van der Straten A, van Damme L, Haberer JE, Bangsberg DR. How well does PREP work? Unraveling the divergent results of PrEP trials for HIV prevention. AIDS. 2012;26(7):F13-9. DOI: 10.1097/QAD.0b013e3283522272.
6. Marrazzo JM, Ramjee G, Nair G, Palanee T, Mkhize B, Nakabiito C, et al. Pre-exposure prophylaxis for HIV in women: daily oral tenofovir, oral tenofovir/emtricitabine or vaginal tenofovir gel in the VOICE study (MTN 003). 20th Conference on Retroviruses and Opportunistic Infections; 2013 Mar 3-6; Atlanta, GA. Abstract 26LB.
7. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010; 329(5996):1168-74.
8. Ross J, Stover J. Use of modern contraception increases when more methods become available: analysis of evidence from 1982-2009. Glob Health Sci Pract. 2013;1(2):203-12.
9. Frost J, Darroch J. Factors associated with contraceptive choice and inconsistent method use, United States, 2004. Perspect Sex Reprod Health. 2008;40(2):94-104.
10. Gray A, Smit J, Manzini N, Beksinska M. Systematic review of contraceptive medicines. "Does choice make a difference?" [Internet] 2006. [cited 2014 Aug 14]. Available from: http://archives.who.int/eml/expcom/expcom15/applications/sections/ContraChoiceReview.pdf
11. Nodin N, Carballo-Dieguez A, Ventuneac AM, Balan IC, Remien R. Knowledge and acceptability of alternative HIV prevention bio-medical products among MSM who bareback. AIDS Care. 2008;20(1):106-15.
12. Heffron R, Ngure K, Mugo N, Celum C, Kurth A, Curran K, et al. Willingness of Kenyan HIV-1 serodiscordant couples to use antiretroviral based HIV-1 prevention strategies. J Acquir Immune Defic Syndr. 2012;61(1):116-9.
13. Galea JT, Kinsler JJ, Salazar X, Lee SJ, Giron M, Sayles JN, et al. Acceptability of pre-exposure prophylaxis as an HIV prevention strategy: barriers and facilitators to pre-exposure prophylaxis uptake among at-risk Peruvian populations. Int J STD AIDS. 2011;22(5):256-62.
14. Liu AY, Kittredge PV, Vittinghoff E, Raymond HF, Ahrens K, Matheson T, et al. Limited knowledge and use of HIV post-and pre-exposure prophylaxis among gay and bisexual men. J Acquir Immune Defic Syndr. 2008;47(2):241-7.
15. Mimiaga MJ, Case P, Johnson CV, Safren SA, Mayer KH. Preexposure antiretroviral prophylaxis attitudes in high-risk Boston area men who report having sex with men: limited knowledge and experience but potential for increased utilization after education. J Acquir Immune Defic Syndr. 2009; 50(1):77-83.
16. Golub SA, Kowalczyk W, Weinberger CL, Parsons JT. Preexposure prophylaxis and predicted condom use among high-risk men who have sex with men. J Acquir Immune Defic Syndr. 2010;54(5):548-55.
17. Dunkle K, Wingood G, Camp C, DiClemente R. Intention to use preexposure prophylaxis among African-American and white women in the United States: results from a national telephone survey. AIDS 2008-XVII International AIDS Conference; Mexico City; 2008. Abstract no. WEPE0258.
18. Van der Elst EM, Mbogua J, Operario D, Mutua G, Kuo C, Mugo P, et al. High acceptability of HIV pre-exposure prophylaxis but challenges in adherence and use: qualitative insights from a phase I trial of intermittent and daily PrEP in at-risk populations in Kenya. AIDS Behav. 2013;17(6):2162-72.
19. Ware NC, Wyatt MA, Haberer JE, Baeten JM, Kintu A, Psaros C, et al. What's love got to do with it? Explaining adherence to oral antiretroviral pre-exposure prophylaxis for HIV-serodiscordant couples. J Acquir Immune Defic Syndr. 2012; 59(5):463-8.
20. Brooks RA, Landovitz RJ, Kaplan RL, Lieber E, Lee SJ, Barkley TW. Sexual risk behaviors and acceptability of HIV pre-exposure prophylaxis among HIV-negative gay and bisexual men in serodiscordant relationships: a mixed methods study. AIDS Patient Care STDS. 2012;26(2):87-94.
21. Terris-Prestholt F, Hanson K, MacPhail C, Vickerman P, Rees H, Watts C. How much demand for New HIV prevention technologies can we really expect? Results from a discrete choice experiment in South Africa. PLoS One. 2013; 8(12):e83193.
22. Greene E, Batona G, Hallad J, Johnson S, Neema S, Tolley EE. Acceptability and adherence of a candidate microbicide gel among high-risk women in Africa and India. Cult Health Sex. 2010;12(7):739-54.
23. Rupp RE, Rosenthal SL. Vaginal microbicides and teenagers. Curr Opin Obstet Gynecol. 2003;15(5):371-5.